Safety and tolerability in combination therapy

Adalat–RAS blocker combinations: similar safety and tolerability profiles to monotherapy

References

  1. Kuschnir E, et al. J Cardiovasc Pharmacol 2004;43:300-5.
  2. Hasebe N, et al. J Hypertens 2005;23:445-53.
  3. Ke Y-N, et al. Cardiovasc Ther 2012;30:326-32.
  4. Taddei S, et al. J Cardiovasc Pharmacol 2003;41:579-85.
  5. Mancia G, et al. J Hypertens 2011;29:600-9.
  6. Saito I, et al. Hypertens Res 2006;29:789-96.